ArticleBone marrow transplantation2012

Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis.

M Hong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.